Therefore, we hypothesized that dual targeting of metabolic (GSK3B) and epigenetic (HDACs) pathways might significantly improve anti-tumor treatment and overcome chemoresistance in ovarian cancer. This evidence concerns the gene GSK3B and ovarian cancer.